#asco26 #leusm Park: Obe-cel was detected in CSF of majority of patients. All in all best outcomes in those with <5% marrow blasts prior to LD+Obe-cel regardless of EMD status.

#asco26 #leusm Park: those w EMD have similar DoR/EFS/OS as those wo EMD. Similar low CRS rates but more ICANS in those with EMD.

#asco26 #leusm Park: Obe-cel outcomes in RR B-ALL with EMD. ORR 59% vs 83% in those w vs wo EMD. Incr to 71%/90% in those w <5% marrow blasts at time of LD.

#asco26 #leusm Goulart: dose dense mCVD/Ino/Blin for RR Ph neg B-ALL. 3yr EFS/OS 69%/79%. Consolidation w CART or alloHCT assoc with better outcomes.

#asco26 #leusm Goulart: dose dense mCVD/Ino/Blin for RR Ph neg B-ALL. 100% CR/CRp/i rate.

#asco26 #leusm Short: hCVAD/Blin w/wo Ino. 100% OS so far in those with Ino.

#asco26 #leusm Short: hCVAD/Blin w/wo Ino. These data continue to look great w caveat that there are more high risk pts in no Ino cohort.

#asco26 #leusm Nasr: with Blin+Ponat 4yr EFS/OS 79%/89% w only 2% allo on CR1.

#asco26 #leusm Nasr: 4yr outcome data for Blin+Ponatinib in Ph+ ALL, including added IT chemo (15) + hCVAD B cycles x 2 in those w WBC >70.

#asco26 #leusm Jabbour: Olve generally well tolerated but only one pt beyond 1yr so far so will need to follow longer term data to determine cumulative AE risks.

#asco26 #leusm Jabbour: Olverembatinib + Blin for persistent MRD+ or TKI intolerant for Ph+ ALL and CML-BC, high response rates despite ~50% w prior exposure to Ponatinib and >60% w prior exposure to Blinatumomab.

#asco26 #leusm Pardee: selinexor added more N/V/D as expected but more went to allo with triple combo and maybe improved OS (not statsig).

#asco26 #leusm Pardee: Selinexor with intensive chemo for ND-AML (excluding CBF and FLT3+). Halted early after Paradigm presented.

#asco26 #leusm Sengar: fewer new infections with reduced hospital contact and cost with A/V vs 7+3.

#asco26 #leusm Sengar: India study of 7+3 vs Aza/Ven21 (not randomized, single center) for ND-AML. Similar induction mortality despite higher age and more high risk dz with A/V.

#tandem26 Ferrara: JAKi facilitates tissue repair whereas steroids actually inhibit it (even though, yes, they do inhibit alloimmune responses). Ferrara’s goal is to move steroids to 2nd line tx for GVHD!

#tandem26 Ferrara: thus far, most GVHD pox/treatment has focused on the intimation and persistence of the alloimmune response, but efforts to improve tissue resistance to damage are important. Eg, intestinal stem cells are damaged by GVHD cytokines. Rux prevents ISC apoptosis, but steroids don’t.

#tandem26 Ferrara: refinement of biomarker + clinical sx based aGVHD stratification (MAGIC composite) now gives greater clarity in predicting outcomes at onset of aGVHD.

#tandem26 Ferrara: beautiful and touching start to his E Don Thomas lecture by dedicating the talk to John Galvin, who we shockingly lost this past year at far, far too young an age.

#tandem26 Unfortunately, I could only make the end of Stella Davies’s Bortin Lecture, but absolute respect to her for using her platform to speak out against the anti-immigrant, anti-democratic trajectory of our current course in America! “We can not sit this one out.” Agree 1000000% !!!

#tandem26 #bmtsm Rafati: in triple neg MF, TET2mut assoc with incr relapse and inferior OS, whereas TET2mut doesn’t affect outcomes with MF with canonical driver mutation.

#tandem26 #bmtsm Rafati: triple neg MF have inferior alloHCT outcomes. Overall conventional high risk gene must not assoc w survival, but TP53m assoc w inferior outcome with any driver mutation.

#tandem26 #bmtsm Rafati: driver mut found in 81.7%. 18% were triple neg. 94% found to have at least one somatic mut, 1/3 with ASXL1.

#tandem26 #bmtsm Rafati: @cibmtr.bsky.social analysis of genetic predictors of alloHCT outcomes in myelofibrosis. Known high risk assoc w ASXL1+nonCALR/MPL muts. N=930 evaluated here w 95 gene assay.

#tandem26 #bmtsm Popat: age and IPSS not correl w outcomes. TP53 mut status was assoc w 3yr PFS/OS 64% with TP53wt vs 50% with TP53m. Relapse >3x higher in TP53m. Impressive outcomes, but the high NRM is problematic, esp for TP53wt — ie at 12mos, only 6% relapse but OS 69% due to the high toxicity.

#tandem26 #bmtsm Popat: N=50 w HR-MDS underwent CLADILLAC allo. Median age 63, 84% matched donors, 94% PBSC. 28% with TP53 abnormalities. 3yr PFS/OS both 60%, relapse 10%, NRM 30%.

#tandem26 #bmtsm Popat: updated outcomes on CLADILLAC conditioning for MAC allo in HR-MDS. ~1/3 cured with current standard approaches. Age 18-70 eligible for this trial. N=50.

#tandem26 #bmtsm Gyurkocza: low precond BTNL3 expression was associated with poor outcomes in those who recd TBI.

#tandem26 #bmtsm Gyurkocza: several genes associated with outcomes when expressed highly precond, especially CCDC144A. At day 0, CD34 and CACNA1 expression assoc with PFS/OS.

#tandem26 #bmtsm Gyurkocza: FluTreo with TBI N=17 vs 14 wo TBI. Bulk marrow RNAseq used with ML assisted analyses.